Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) belonging to the Khavinson peptide family.(1) Recent investigations propose its potential for instigating primary reparative mechanisms across diverse tissues, particularly in the case of prostate cell cultures. Its influence may extend as far as the modulation of chromatin structural dynamics, with a discernible potential to activate genes in a previously repressed state, thereby inducing alterations in chromosomal dynamics.

Observable impacts noted by researchers encompass an elevated frequency of sister chromatid exchanges and heightened Ag-positive nucleolus organizer regions, indicative of intensified chromosomal exchange activities and modifications in ribosomal RNA gene function.

Moreover, Prostamax peptide may exhibit a propensity to decrease the occurrence of large segments within C-pericentromeric heterochromatin, suggestive of a decondensation effect on chromatin. Within prostatic gland tissue cultures, Prostamax peptide may emerge as a facilitator of reparative processes, exhibiting potential in diminishing inflammation and thwarting sclerotic and atrophic phenomena.


Prostamax Peptide and the Prostate Gland

Chronic prostatitis, known as chronic inflammation of the prostate is a widely studied condition. Compelling scientific data suggests a link between chronic prostatitis and the development of cardiovascular disease and even cancer.(2)

In rat models, Prostamax peptide has been suggested to potentially act as a mitigator of prostatitis. Rats subjected to a 15-day Prostamax peptide regimen appeared to exhibit reduced swelling of the prostate gland, diminished vascular congestion (hyperemia), and decreased immune cell infiltration. Notably, a reported decrease in scarring within the prostate hinted at a deceleration or even cessation of pathological remodeling associated with inflammation. While the study duration and rat sample size did not permit an assessment of Prostamax’s impact on cancer risk, the scientists suggest “suggested that peptide such as Prostamax may have potential for the stimulation of reparative processes in the appropriate tissues while aging.”(3)

A further investigation examined the potential of Prostamax peptide within animal models of chronic aseptic prostatitis.(4) Thorough experimental studies indicated a possible capacity to mitigate the severity of chronic inflammation in murine models, encompassing aspects such as swelling, vessel hyperemia, and lymphoid infiltration.

The experimental design involved subjecting murine models to a procedure specifically designed to induce chronic aseptic inflammation in the prostate gland. Following this induction, the models were exposed to Prostamax peptide, and its impact was subsequently assessed in comparison to active controls. The primary objective was to evaluate the potential of Prostamax peptide in ameliorating the effects of chronic prostatitis and its associated complications, juxtaposed against the efficacy of active controls. The authors posit that Prostamax peptide exposure may have led to the alleviation of inflammation-related symptoms, including swelling, vessel hyperemia, and cellular infiltration commonly observed in murine models of chronic prostatitis. Researchers commented that particularly noteworthy was its potential in restraining the development of sclerotic and atrophic processes in the prostate gland models—complications frequently encountered in such models.

Its hypothetical action in averting complications appeared more pronounced when compared to comparator agents, indicating a potential superiority in this regard. Furthermore, Prostamax peptide demonstrated a potential capacity to enhance mating activity in the animal models, a finding that hints at broader research prospects.


Prostamax Peptide and Cell Aging

One investigation underscores the potential impact of Prostamax peptide on the chromatin structure within lymphocytes.(5) Chromatin, the intricate assembly of DNA and proteins within cells, undergoes specific stages of denaturation at distinct temperatures and energy states, designated as T(d)VII and T(d)VIII.

Prostamax peptide appears to induce discernible alterations in this chromatin structure. Specifically, it instigates a redistribution of heat across two endotherms, T(d)III and T(d)IV, resulting in a decrease in their temperatures by 2.9 and 1.0 degrees Celsius, respectively. This redistribution and temperature shift may be associated with a relaxation in the chromatin structure, particularly the transition of the 30-nm-thick fiber into a 10-nm filament.

Moreover, there is an indication that Prostamax peptide might induce minor structural modifications in the nucleosomal organization within the chromatin. This is manifested by a slight reduction in the temperatures of T(d)VIII and T(d)VII in lymphocytes exposed to Prostamax peptide compared to control cells. These alterations are posited to arise from adjustments in the structural organization of both the 10-nm filament and the 30-nm fiber.

Of particular significance in the context of cell aging is the fact that DNA condensation represents a normal, albeit undesirable, consequence of the cell aging process. DNA condensation serves as a prominent driver of both senescence and apoptosis, making it a pivotal mechanism in the cell’s aging trajectory. By unraveling DNA, Prostamax peptide essentially imparts a more youthful genetic profile to cells. The outcomes include heightened cellular proliferation, reduced apoptosis (programmed cell death), and enhanced protein expression and overall cellular function.

Notably, Prostamax peptide and analogous epigenetically active peptides are naturally present in long-lived rodent species such as the African mole rat, whereas they are absent in short-lived species.(6) This observation suggests a direct correlation between the epigenetic potential with peptides like Prostamax and the processes of cell aging.


Prostamax Peptide and the Immune System

Despite researchers’ hypothesis that the peptide is tissue-specific, Prostamax appears to potentiate an influence beyond the prostate on various cell types. Notable research findings suggest its potential may manifest in ribosomes and densely packed chromatin within lymphocytes. Analogous to Epithalon and Vilon, Prostamax is speculated to contribute to an augmented expression of ribosomes, pivotal in the translation of mRNA into proteins. Additionally, it is speculated to facilitate the decondensation of densely packed chromatin, possibly enhancing gene accessibility for transcription into mRNA. Consequently, Prostamax peptide appears to establish a foundation for heightened gene expression across all levels, instigating functional changes in lymphocytes.(5,7)

The impact of Prostamax peptide on the immune system transcends theoretical considerations. Empirical research indicates its efficacy in alleviating indicators of chronic prostate inflammation, encompassing reductions in swelling, hyperemia, and lymphocyte infiltration. This outcome is attributed to Prostamax’s influence on lymphocytes and their regulatory role in immune responses, as well as the peptide’s proposed involvement in normalizing the growth and differentiation of prostate cells.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.




  1. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Adv Gerontol. 2006;19:93-6. Russian. PMID: 17152728.
  2. “Treating chronic prostatitis,” Harvard Health, Dec. 21, 2017.
  3. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Adv Gerontol. 2006;19:93-6. Russian. PMID: 17152728.
  4. Borovskaya, T. G., Pakhomova, A. V., Vychuzhanina, A. V., Poluektova, M. E., Fomina, T. I., Ermolaeva, L. A., & Neplochov, E. A. (2013). Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications. Modern Research in Inflammation, 2013.
  5. Meskhi T, Khachidze D, Barbakadze Sh, Madzhagaladze G, Gorgoshidze M, Monaselidze D, Lezhava T, Tadumadze N. The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]. Biofizika. 2004 Nov-Dec;49(6):1091-3. Russian. PMID: 15612551.
  6. Khavinson VK, Kormilets DY, Mar’yanovich AT. Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan. Bull Exp Biol Med. 2017 Sep;163(5):671-676. doi: 10.1007/s10517-017-3876-x. Epub 2017 Sep 25. PMID: 28948547.
  7. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004 Jan;137(1):78-81. doi: 10.1023/b:bebm.0000024393.40560.05. PMID: 15085253.
    Your Cart
    Your cart is empty